Stock Events

Stock Events

Fennec Pharmaceuticals 

$0.000000
14
-$1,380.00-100% Friday 22:07

Statistics

Day High
-
Day Low
-
52W High
9.24
52W Low
5.6
Volume
-
Avg. Volume
212,316
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Sep 26
$0.03
Sep 25
$0.03
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

1AprExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
-0.22
-0.13
-0.04
0.04
Expected EPS
0.0419508738
Actual EPS
N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company that competes with Fennec Pharmaceuticals in the oncology sector, particularly in developing treatments for cancer-related conditions.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a leading pharmaceutical company that develops cancer therapies, directly competing with Fennec Pharmaceuticals' focus on oncology.
Novartis
NVS
Mkt Cap292.35B
Novartis AG competes in the pharmaceutical industry by offering a wide range of oncology drugs, which puts it in direct competition with Fennec Pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, develops and markets oncology drugs, competing with Fennec Pharmaceuticals in the cancer treatment space.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is involved in the discovery, development, and marketing of cancer drugs, making it a competitor to Fennec Pharmaceuticals in the oncology field.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, with its strong portfolio in oncology, competes with Fennec Pharmaceuticals in developing and marketing cancer treatments.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a significant presence in the oncology sector, developing treatments that compete with Fennec Pharmaceuticals' cancer-focused therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is known for its innovative therapies in oncology, among other areas, competing with Fennec Pharmaceuticals in the cancer treatment market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. focuses on human therapeutics, including oncology, which puts it in competition with Fennec Pharmaceuticals in the development of cancer treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in the development of oncology drugs, competing with Fennec Pharmaceuticals in the cancer therapy market.

About

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Show more...
CEO
Jeffrey S. Hackman
Employees
35
Country
Canada

Listings

STU
DE
RV41.STU
MU
DE
RV41.MU
F
DE
RV41.F
XNAS
US
FENC

0 Comments

Share your thoughts

FAQ

What is Fennec Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Fennec Pharmaceuticals stocks are traded under the ticker ADH.
Is Fennec Pharmaceuticals stock price growing?▼
ADH stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Fennec Pharmaceuticals has showed a +27.74% increase.
Does Fennec Pharmaceuticals pay dividends?▼
Yes, ADH dividends are paid annual. The last dividend per share was 0.03 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Fennec Pharmaceuticals have?▼
As of September 04, 2026, the company has 35 employees.
In which sector is Fennec Pharmaceuticals located?▼
Fennec Pharmaceuticals operates in the Health & Wellness sector.
When did Fennec Pharmaceuticals complete a stock split?▼
Fennec Pharmaceuticals has not had any recent stock splits.
Where is Fennec Pharmaceuticals headquartered?▼
Fennec Pharmaceuticals is headquartered in RESEARCH TRIANGLE PARK, Canada.